Publication | Closed Access

Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer

ThrombosisVenous ThrombosisPancreatic CancerHepatologyMedicineHepatobiliary TumorGastroenterologyUpper GastrointestinalAnticoagulantSurgeryPharmacotherapyLiver CancerOral RivaroxabanOncologyRadiation OncologyCancer Research